MIR223 (MicroRNA 223)

Common treatments such as anthracyclines and targeted therapies like trastuzumab are known to disrupt cardiac function through mechanisms including mitochondrial dysfunction, dysregulation of ion channels, and induction of apoptosis...High-throughput technologies, including aptamers and proximity extension assays, have further enhanced the ability to screen for biomarkers with increased specificity and sensitivity. Integrating these traditional and emerging biomarkers provides a comprehensive approach for early detection of CTR-CVT, ultimately helping improve patient outcomes in cancer therapy.

miR-223-3p, both alone and in combination with miR-1290 and miR-1246, demonstrated optimal performance in distinguishing HRR from SIRR patients (AUC = 0.68, 95% CI: 0.52-0.84; AUC = 0.69, 95% CI: 0.53-0.84, respectively). These preliminary findings indicate that miR-223-3p, whether used independently or in conjunction with miR-1246 and miR-1290, may serve as promising non-invasive MRD biomarkers in pediatric ALL. Further validation in larger patient cohorts is necessary to corroborate these results.

The detection of cancer-like molecular signatures in asymptomatic fish highlights potential for early diagnosis and monitoring. These findings establish a molecular framework for investigating PSS etiology, inform biomarker development, and underscore the need to evaluate environmental and infectious triggers in scombrid aquaculture.

Notable differences in miRNA expression profiles were revealed for the patients with brain metastases from lung cancer, suggesting the role of the selected miRNAs in cancer metastasis to the CNS. However, while our analysis provides exploratory insights, the findings should be interpreted with caution and require validation in larger, independent cohorts before any clinical or translational implications can be established.

Multivariate Cox regression showed that a model of downregulated miR-16-5p and upregulated miR-451a was significantly associated with poorer survival (p = 0.023). This study indicates the future potential of exomiRs as diagnostic and prognostic liquid biopsy markers for vulvar cancer.

In summary, new miRNA signatures of relevance in B-AL and B-Ly could be recognized in this study. Studies in larger cohorts are required to further validate these findings.

These findings indicate that a panel of circulating miRNAs may serve as a useful tool for the diagnosis and prognosis of intrahepatic cholangiocarcinoma, warranting further validation in larger cohorts. Additionally, the accuracy of diagnostic tests may be improved by increasing the sample size and including diverse clinical subgroups to enhance the robustness and generalizability of the results.

Therefore, the NLRP3 inflammasome represents a key player in cancer development, and its regulation by miRNAs highlights its importance and clinical potential. This review summarizes mechanistic and clinical knowledge on the biology of NLRP3, highlights its dual role in cancer hallmarks, and discusses the therapeutic promise of targeting the NLRP3-miRNA axis in the management of oral cancer.

Combined miRNA profiling highlights miR-222 and, to a lesser extent miR-155, as consistent indicators of myeloid disease transformation. While further validation in larger and genetically stratified cohorts is warranted, these findings support the potential contribution of miRNA signatures to diagnostic evaluation and risk stratification in MDS and AML, in line with precision hematology approaches.

DNA methylation and microRNA biomarkers hold strong promises for non-invasive CRC screening. Multi-marker panels demonstrate superior diagnostic accuracy and may provide a cost-effective, scalable approach for early CRC detection in resource-limited settings.

Therefore, those miRNAs have the potential to serve as early and sensitive biomarkers for TAA-induced cholangiocarcinoma. Notably, no previous study has demonstrated the role of miR-146-5p on cancer development.

Circulating miRNA signatures represent promising non-invasive biomarkers for early PM detection and prognostic stratification, particularly in epithelioid cases. Incorporation of these biomarkers into clinical workflows could pave the way for more personalized treatment strategies and optimize patient selection for surgery.